DEFINITIVE CONTRACT
Active75F40126C00098
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$733.5K
obligated · signed 2 months ago
NEXT GENERATION PROCESS DEVELOPMENT AND QUALITY CONTROL IN PROTEIN LYOPHILIZATION USING MECHANISTIC AND AI APPROACHES
Performance timeline
Start
Sep 11, 2026
End
Sep 10, 2028
with all options
Loading status
Estimated start: Sep 10, 2027
RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBH
Contract 75F40126C00098
UEI
JMW6R9VB27L9
Parent Company
RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBH
Capabilities & Certifications
Headquarters Location
Current Obligation
$733,525
Base + Exercised Options
$733,525
Total Ceiling Value
$733,525
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.